Manos, Kate
Chong, Geoffrey
Keane, Colm
Lee, Sze-Ting
Smith, Charmaine
Churilov, Leonid
McKendrick, Joseph
Renwick, William
Blombery, Piers
Burgess, Melinda
Nelson, Niles Elizabeth
Fancourt, Tineke
Hawking, Joanne
Lin, Wendi
Scott, Andrew M.
Barraclough, Allison http://orcid.org/0000-0003-1615-0540
Wight, Joel http://orcid.org/0000-0002-3216-2392
Grigg, Andrew
Fong, Chun Yew
Hawkes, Eliza A. http://orcid.org/0000-0002-0376-2559
Funding for this research was provided by:
Merck KGaA
Scott Canning Tour de Cure Wilson Centre for Lymphoma Genomics
Article History
Received: 7 November 2022
Revised: 19 February 2023
Accepted: 27 February 2023
First Online: 11 March 2023
Competing interests
: KM has received travel expenses from Bristol Myers Squibb. GC has acted as a consultant/advisor for Bristol Myers Squibb Foundation (paid to institution) and received research funding from AstraZeneca, Bayer, Bristol-Myers Squibb, Hutchison MediPharma, Isofol Medical, Merck Serono, Pharmacyclics, Regeneron, SERVIER (all paid to institution). CK has received honoraria from Roche, Beigene, Karyopharm Therapeutics. WR has received research funding from GSK, Janssen, MorphoSys and Incyte (all paid to institution). AS has acted as a consultant for Imagion; received research funding from Telix, Curis, ITM, Adalta, Fusion, Astra Zeneca, EMD Serono, Cyclotek, AVID/Lilly and Merck (all paid to institution); and holds patents relating to antibodies to EGFR, HER2, PDGF-CC, FN-14, GM-CSF and EPhA3. AB has acted as a speaker for Roche and as a consultant/advisor for Gilead. JW has received honoraria and travel subsidies from Abbvie and Janssen; and is on the advisory board for Abbive and Alexion. CF has received honoraria from Abbvie, Amgen, Bristol-Myers Squibb, Novartis and Pfizer; has acted as a consultant/advisor for Abbvie, Amgen, Astellas Pharma, Bristol-Myers Squibb, Novartis and Pfizer; and has received research funding from Amgen and Astellas Pharma. EAH has received research funding Bristol Myers Squibb/Celgene, Merck KgA, Astra Zeneca, and F. Hoffmann-La Roche (all paid to institution); has acted as a consultant/advisor for F. Hoffmann-La Roche, Antigene, Bristol Myers Squibb, Astra Zeneca, Novartis, Merck Sharpe Dohme, Specialised therapeutics and Gilead; has acted as a speaker for Roche, Astra Zeneca, Janssen, and Regeneron. The remaining authors declare no competing financial interests.